{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:25:22Z","timestamp":1787250322360,"version":"build-2736575974"},"reference-count":79,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis. Asundexian, a selective Factor XIa inhibitor, represents a promising advancement in this evolving therapeutic landscape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review synthesizes available preclinical and clinical evidence on Asundexian, with a focus on its pharmacological mechanism, efficacy, safety profile, and potential clinical applications. Key data from major clinical trials, including PACIFIC\u2010AF and PACIFIC\u2010STROKE, were reviewed to evaluate its role in contemporary anticoagulation therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical trial evidence indicates that Asundexian effectively reduces the incidence of stroke and systemic embolism in patients with atrial fibrillation and those at risk of recurrent ischemic stroke. Importantly, these benefits are achieved with a lower risk of major bleeding compared to conventional anticoagulants. Asundexian's fixed dosing regimen, oral administration, and lack of routine coagulation monitoring enhance treatment convenience and patient adherence. Emerging data also suggest potential applicability in other conditions requiring long\u2010term anticoagulation, such as venous thromboembolism and acute coronary syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Asundexian offers a novel and potentially safer approach to anticoagulation by selectively targeting Factor XIa, balancing thromboembolic protection with reduced bleeding risk. While early clinical results are encouraging, further large\u2010scale and long\u2010term studies are required to establish its safety and efficacy across diverse patient populations. Asundexian has the potential to redefine standards of care in anticoagulation therapy and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.71795","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:19:13Z","timestamp":1773721153000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Asundexian Versus Apixaban in Patients With Atrial Fibrillation"],"prefix":"10.1002","volume":"9","author":[{"given":"Zara","family":"Saeed","sequence":"first","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Ariba","family":"Zehra","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumyya","family":"Tariq","sequence":"additional","affiliation":[{"name":"Fauji Foundation Hospital  Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio Pun","family":"Zumaran","sequence":"additional","affiliation":[{"name":"Universidad Autonoma de Guadalajara  Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Kotte","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Hameed","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad","family":"Talat","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Taj","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-4187","authenticated-orcid":false,"given":"Jahanzeb","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Perveen","sequence":"additional","affiliation":[{"name":"Department of Medicine Ibn e Seena Hospital Kabul Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"issue":"12","key":"e_1_2_11_9_1","first-page":"1486","article-title":"New Oral Anticoagulants and the Risk of Intracranial Hemorrhage","volume":"70","author":"Chatterjee S.","year":"2013","journal-title":"JAMA Neurology"},{"issue":"10","key":"e_1_2_11_10_1","first-page":"967","article-title":"Non\u2013Vitamin K Antagonist Oral Anticoagulants in Patients With Advanced Kidney Disease","volume":"133","author":"Chan K. E.","year":"2016","journal-title":"Circulation"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.040"},{"issue":"3","key":"e_1_2_11_12_1","first-page":"404","article-title":"Anticoagulants in Heart Disease: Current Status and Perspectives","volume":"128","author":"Dangas G. D.","year":"2021","journal-title":"Circulation Research"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00019"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02446.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00456-1"},{"issue":"2","key":"e_1_2_11_16_1","first-page":"478","article-title":"Bay 2433334, a Novel, Oral, Direct Factor XIa Inhibitor: First Evaluation in Humans","volume":"109","author":"Thomas D.","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_11_17_1","first-page":"A49","article-title":"Apixaban, Rivaroxaban, and Asundexian: Emerging Perspectives in Oral Anticoagulation","volume":"25","author":"Alexander J. H.","year":"2023","journal-title":"European Heart Journal Supplements"},{"issue":"11","key":"e_1_2_11_18_1","first-page":"1475","article-title":"Factors Xa and IIa Inhibitors: The Next Generation of Anticoagulants","volume":"129","author":"Weitz J. I.","year":"2017","journal-title":"Blood"},{"issue":"15","key":"e_1_2_11_19_1","first-page":"1541","article-title":"Association Between Edoxaban Dose, Concentration, Anti\u2010Factor Xa Activity, and Outcomes: An Analysis of the ENGAGE AF\u2010TIMI 48 Trial","volume":"66","author":"Ruff C. T.","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00019"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02446.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0307"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170818112904"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2023.295"},{"issue":"4","key":"e_1_2_11_25_1","first-page":"694","article-title":"Antisense Oligonucleotides Targeted to Factor XI Reduce Thrombosis in Models of Venous Stasis and Arterial Thrombosis","volume":"11","author":"Crosby J. R.","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"e_1_2_11_26_1","first-page":"478","article-title":"Bay 2433334, a Novel, Oral, Direct Factor XIa Inhibitor: First Evaluation in Humans","volume":"109","author":"Thomas D.","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"e_1_2_11_27_1","first-page":"1640","article-title":"Pharmacokinetics and Pharmacodynamics of the Oral Factor XIa Inhibitor Asundexian in Healthy Volunteers","volume":"20","author":"Perera V.","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_11_28_1","first-page":"A49","article-title":"Emerging Oral Factor XIa Inhibitors: Clinical Development Update","volume":"25","author":"Alexander J. H.","year":"2023","journal-title":"European Heart Journal Supplements"},{"key":"e_1_2_11_29_1","first-page":"60","article-title":"The Effect of Factor XIa Inhibition on Thrombin Generation and Bleeding Risk","volume":"185","author":"Kremers R. M. W.","year":"2020","journal-title":"Thrombosis Research"},{"issue":"2","key":"e_1_2_11_30_1","article-title":"Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?","volume":"3","author":"Spronk H. M.","year":"2014","journal-title":"Journal of the American Heart Association"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000919"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"issue":"9","key":"e_1_2_11_33_1","first-page":"639","article-title":"Next\u2010Generation Anticoagulants: Moving Beyond Factor Xa and Thrombin","volume":"21","author":"Chan N. C.","year":"2022","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"e_1_2_11_34_1","first-page":"30","article-title":"Factor XI as a Drug Target\u2014Biological Basis and Therapeutic Potential","volume":"16","author":"Koch A.","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-880849"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405760"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00456-1"},{"issue":"10379","key":"e_1_2_11_38_1","first-page":"1461","article-title":"Factor XIa Inhibition With Asundexian After Acute Non\u2010Cardioembolic Ischemic Stroke (PACIFIC\u2010STROKE)","volume":"401","author":"Diener H. C.","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"e_1_2_11_39_1","first-page":"699","article-title":"Anticoagulation With Factor XIa Inhibitors in Secondary Stroke Prevention and Cardiovascular Disease","volume":"147","author":"Bhatt D. L.","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"e_1_2_11_40_1","first-page":"735","article-title":"Factor XI and Factor XII as Targets for New Anticoagulants","volume":"140","author":"Weitz J. I.","year":"2022","journal-title":"Blood"},{"issue":"2","key":"e_1_2_11_41_1","first-page":"310","article-title":"Asundexian, an Oral Factor XIa Inhibitor: Pharmacology and Clinical Development","volume":"21","author":"Perera V.","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"issue":"6","key":"e_1_2_11_43_1","first-page":"463","article-title":"Anticoagulants Targeting Factor XI and XII","volume":"20","author":"Kochanek P. M.","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"e_1_2_11_44_1","first-page":"33","article-title":"Factor XIa Inhibition and Preservation of Hemostasis","volume":"123","author":"Kremers R.","year":"2023","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_11_45_1","first-page":"1382","article-title":"Safety and Efficacy of Asundexian Versus Apixaban in Atrial Fibrillation (PACIFIC\u2010AF)","volume":"387","author":"Piccini J. P.","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_46_1","first-page":"1799","article-title":"Factor XI Inhibition in Patients With Acute Myocardial Infarction","volume":"387","author":"Anand S. S.","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_47_1","first-page":"997","article-title":"Oral Factor XIa Inhibition for Prevention After Ischemic Stroke (PACIFIC\u2010STROKE)","volume":"400","author":"Lassen M. R.","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"e_1_2_11_48_1","first-page":"15","article-title":"Clinical Pharmacology of Factor XIa Inhibitors","volume":"62","author":"Perera V.","year":"2023","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1095"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-018-1729-8"},{"issue":"2","key":"e_1_2_11_52_1","first-page":"177","article-title":"Pharmacokinetics of Asundexian","volume":"63","author":"Perera V.","year":"2023","journal-title":"Journal of Clinical Pharmacology"},{"key":"e_1_2_11_53_1","first-page":"152","article-title":"Novel Oral Anticoagulants Compared With LMWH: Clinical Impact","volume":"163","author":"Eriksson B. I.","year":"2018","journal-title":"Thrombosis Research"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017549"},{"key":"e_1_2_11_56_1","first-page":"1382","article-title":"PACIFIC\u2010AF Trial Results","volume":"387","author":"Piccini J. P.","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_57_1","first-page":"402","article-title":"Secondary Stroke Prevention: Current and Emerging Strategies","volume":"19","author":"Diener H. C.","year":"2020","journal-title":"Lancet Neurology"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"e_1_2_11_59_1","first-page":"997","article-title":"PACIFIC\u2010STROKE Trial","volume":"400","author":"Lassen M. R.","year":"2022","journal-title":"Lancet"},{"key":"e_1_2_11_60_1","first-page":"1342","article-title":"Venous Thromboembolism: New Anticoagulants","volume":"395","author":"Weitz J. I.","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"issue":"7","key":"e_1_2_11_62_1","first-page":"871","article-title":"Factor XIa Inhibition for Venous Thromboembolism: Emerging Evidence","volume":"121","author":"Bounameaux H.","year":"2021","journal-title":"Thrombosis and Haemostasis"},{"issue":"40","key":"e_1_2_11_63_1","first-page":"4194","article-title":"Anticoagulation Challenges: Balancing Efficacy and Safety","volume":"42","author":"Lip G. Y. H.","year":"2021","journal-title":"European Heart Journal"},{"issue":"14","key":"e_1_2_11_64_1","first-page":"2845","article-title":"Phase II Trials of Factor XIa Inhibitors: Lessons Learned","volume":"5","author":"Cuker A.","year":"2021","journal-title":"Blood Advances"},{"key":"e_1_2_11_65_1","first-page":"10","article-title":"Long\u2010Term Safety of Anticoagulants: A Systematic Review","volume":"214","author":"Brown K.","year":"2022","journal-title":"Thrombosis Research"},{"key":"e_1_2_11_66_1","first-page":"A37","article-title":"Next\u2010Generation Anticoagulants: Translating Phase II Data Into Clinical Practice","volume":"24","author":"Ruff C. T.","year":"2022","journal-title":"European Heart Journal Supplements"},{"issue":"19","key":"e_1_2_11_67_1","first-page":"2398","article-title":"Prosthetic Heart Valves and Anticoagulation Therapy","volume":"75","author":"Dangas G. D.","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"e_1_2_11_68_1","first-page":"249","article-title":"Thrombophilia and Anticoagulation Management","volume":"32","author":"Bates S. M.","year":"2018","journal-title":"Blood Reviews"},{"key":"e_1_2_11_69_1","article-title":"Global Accessibility of NOACs: Economic and Health Policy Perspectives","volume":"11","author":"Kakkar A. K.","year":"2021","journal-title":"Journal of Global Health"},{"key":"e_1_2_11_70_1","unstructured":"ClinicalTrials.gov Asundexian Ongoing Phase III Studies (PACIFIC Program). Identifier: NCT05030142 (ClinicalTrials.gov 2025)."},{"key":"e_1_2_11_71_1","first-page":"1","article-title":"The Pacific Clinical Trial Program: Overview","volume":"259","author":"Patel M. R.","year":"2023","journal-title":"American Heart Journal"},{"issue":"7","key":"e_1_2_11_72_1","first-page":"1142","article-title":"Factor XIa Inhibitors as Potential First\u2010Line Anticoagulants","volume":"123","author":"Kubitza D.","year":"2023","journal-title":"Thrombosis and Haemostasis"},{"issue":"12","key":"e_1_2_11_73_1","first-page":"1212","article-title":"Antiplatelet and Anticoagulant Combination Strategies in Cardiovascular Disease","volume":"43","author":"Capodanno D.","year":"2022","journal-title":"European Heart Journal"},{"issue":"7","key":"e_1_2_11_74_1","first-page":"510","article-title":"Precision Medicine in Anticoagulation","volume":"144","author":"Mega J. L.","year":"2021","journal-title":"Circulation"},{"issue":"22","key":"e_1_2_11_75_1","first-page":"2065","article-title":"Individualized Approaches to Anticoagulation: The Role of Factor XIa Inhibition","volume":"81","author":"Connolly S. J.","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_11_76_1","article-title":"Factor XIa Inhibitors: The Next Frontier","volume":"56","author":"Weitz J. I.","year":"2022","journal-title":"Blood Reviews"},{"issue":"2","key":"e_1_2_11_77_1","first-page":"310","article-title":"Mechanistic Insights Into Asundexian","volume":"21","author":"Perera V.","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"e_1_2_11_78_1","first-page":"223","article-title":"Practical Advantages of Factor XIa Inhibitors","volume":"107","author":"Testa S.","year":"2021","journal-title":"European Journal of Haematology"},{"key":"e_1_2_11_79_1","first-page":"A45","article-title":"Remaining Gaps in Novel Anticoagulant Use","volume":"24","author":"Lip G. Y. H.","year":"2022","journal-title":"European Heart Journal Supplements"},{"issue":"9","key":"e_1_2_11_80_1","first-page":"1345","article-title":"Asundexian and the Future of Anticoagulation: Clinical Perspectives","volume":"123","author":"Anand S. S.","year":"2023","journal-title":"Thrombosis and Haemostasis"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.71795","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:46:43Z","timestamp":1787248003000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.71795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/hsr2.71795"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.71795","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71795"}}